The study was published in October in the Journal of Clinical Oncology. It found that overall Imfinzi was well tolerated and safety was consistent with previous trials, according to a June 17 news release from AstraZeneca.
Endometrial cancers that are mismatch repair deficient are often seen in 25% to 30% of patients, according to a study published in the International Journal of Gynecological Cancer.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.